Who is sponsoring NCT02242201?

NCT02242201 is sponsored by Mayo Clinic.

What condition does NCT02242201 study?

NCT02242201 studies Total Hip Arthroplasty.

What drugs are being tested in NCT02242201?

Interventions: PNB Bupivacaine, PAI Ropivacaine, PAI liposomal bupivacaine, Epinephrine, Ketorolac.

What is the status of NCT02242201?

NCT02242201 is currently COMPLETED.

Last reviewed 2018-03-21 · How we verify

Prospective, Randomized Controlled Trial Comparing Continuous Posterior Lumbar Plexus Nerve Block vs Periarticular Injection With Ropivacaine or Liposomal Bupivacaine (Exparel®) on Patients Undergoing Total Hip Arthroplasty

NCT02242201 Phase 4 COMPLETED Results posted

Total hip arthroplasty is a one of the most commonly performed surgical procedures with increasing numbers anticipated over the next several decades. The purpose of this study was to find a better way to make patients comfortable after their hip surgery. Three different ways of providing pain relief were compared, a peripheral nerve block in the lower back outside of the spinal space (using bupivacaine, a numbing medicine), or injections around the hip joint with one of two different medicines, either Ropivacaine or Liposomal Bupivacaine (Exparel®).

Details

Lead sponsor	Mayo Clinic
Phase	Phase 4
Status	COMPLETED
Enrolment	165
Start date	2014-09
Completion	2016-09

Conditions

Total Hip Arthroplasty

Interventions

PNB Bupivacaine
PAI Ropivacaine
PAI liposomal bupivacaine
Epinephrine
Ketorolac

Primary outcomes

Maximum Postoperative Pain Score — Post-Operative Day 1 (0600-1200)
Pain was measured on an ascending numeric rating scale (NRS) from 0-10 where 1-3 equaled mild pain, 4-6 equaled moderate pain, 7-9 equaled severe pain, and 10 equaled worst possible pain.

Countries

United States